Posted on January 11, 2012
Deadline: March 16, 2012

Prostate Cancer Foundation Invites Highly Experienced Investigators Worldwide to Apply for Special Challenge Award Research Program

The Prostate Cancer Foundation is inviting applications for the PCF-Honorable A. David Mazzone Special Challenge Award Research Program.

Designed to support large-scale team-driven research projects, the program provides two-year awards totaling $1 million.

Proposals must be from teams of at least three highly experienced investigators capable of devoting unique scientific expertise to the solution of a significant problem in prostate cancer research. A team may be assembled from one institution, or several, located anywhere in the world.

These awards will focus on funding treatment sciences. Research with a high probability of near-term patient benefit is required in the following topic areas: translational research in metabolism/adiposity/nutrition/survivorship; molecular imaging in both primary and metastatic disease; co-targeting tumor microenvironment; first-in-field research on new targets in metastatic disease systemic treatment; mechanisms of resistance to new treatments for advanced prostate cancer; and diagnostics and biomarkers that differentiate indolent from metastatic prostate cancer.

Investigators representing nonprofit academic research centers worldwide are eligible to apply. Investigators from for-profit companies and government-sponsored institutions are ineligible.

Visit the PCF Web site for the complete Request for Applications and application submission procedures. Applications will be accepted online from February 15 to March 16, 2012.

Contact:
Link to Complete RFP

Primary Subject: Medical Research
Geographic Funding Area: National

Looking for additional funders in the field of Medical Research?
Foundation Directory Online allows you to search the entire universe of U.S. grantmakers. Target your search by field of interest, type of support, geographic focus, and more. Find the plan that's right for you»